Shattuck Labs Inc investor relations material

Shattuck Labs is a clinical-stage biotechnology company developing therapeutics for the treatment of cancer and autoimmune disease. The company was incorporated in 2016, and is focused on developing SL-172154 for the treatment of ovarian, fallopian tube and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma.